scholarly journals Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer

Gut and Liver ◽  
2020 ◽  
Vol 14 (1) ◽  
pp. 135-143 ◽  
Author(s):  
Jeung Eun Lee ◽  
Hee Seung Lee ◽  
Moon Jae Chung ◽  
Jeong Youp Park ◽  
Seung Woo Park ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Predictive Factors ◽  
Advanced Pancreatic Cancer ◽  
Second Line ◽  
Factors Affecting ◽  
Second Line Chemotherapy ◽  
Gemcitabine Refractory ◽  
Line Chemotherapy

FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

2012 ◽  
Vol 69 (6) ◽  
pp. 1641-1645 ◽  
Author(s):  
Alberto Zaniboni ◽  
Enrico Aitini ◽  
Sandro Barni ◽  
Daris Ferrari ◽  
Stefano Cascinu ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Pancreatic Cancer ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Multicenter Phase ◽  
Line Chemotherapy

scholarly journals P-0119 Beneficial Trends of Second Line Chemotherapy in Advanced Pancreatic Cancer

2012 ◽  
Vol 23 ◽  
pp. iv65
Author(s):  
Milton Jose Barros e Silva ◽  
Joyce Maria L. Maia ◽  
Adriana Regina Goncalves Ribeiro ◽  
Ludmilla T.D. Chinen ◽  
Tadeu Paiva Junior ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Advanced Pancreatic Cancer ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

The role of S-1 in gemcitabine-refractory pancreatic cancer: A retrospective single-institution study

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15648-e15648
Author(s):  
Y. Nakai ◽  
H. Isayama ◽  
T. Sasaki ◽  
N. Sasahira ◽  
K. Hirano ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Factors ◽  
Hazard Model ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Gemcitabine Refractory ◽  
The University ◽  
Cox Hazard Model ◽  
The Impact ◽  
Line Chemotherapy

e15648 Background: S-1 was reported to be active against gemcitabine (Gem)-refractory pancreatic cancer (PaC) in Japan and was introduced in February 2005 in our institution. The aim of this study was to elucidate the impact of S-1 on prognosis of patients with Gem- refractory PaC. Methods: A total of 108 patients (pts) with advanced PaC who were treated with Gem and had disease progression (PD) at the University of Tokyo Hospital were analyzed. The introduction rates of second-line chemotherapy and the causes of introduction failure were assessed. Prognostic factors for residual survival (RS) for Gem-refractory PaC were analyzed by the Cox proportional hazard model. Results: Of 108 pts with Gem-refractory PaC, 47 pts (PreS-1 Group) had PD before February 2005, the time of S-1 introduction in our institution, and 61 pts (PostS-1 Group) after February 2005. There were no differences in baseline characteristics at PD for Gem between PreS-1 and PostS-1 Groups, except for metastasis to peritoneum more prevalent in PreS-1 Group (44.7% in PreS-1 Group and 23.0% in PostS-1 Group, p=0.023). The introduction rate of second-line chemotherapy increased from 12.8% in PreS-1 Group to 45.9% in PostS-1 Group. Second-line chemotherapy was administered in 34 pts, 29 by S-1, 4 by 5-FU-based chemoradiation, and 1 by 5-FU. The causes of introduction failure of second line chemotherapy were poor PS in 64.9%, patients’ refusal in 16.2%, infection in 2.7%, adverse effects of Gem in 1.4% and jaundice in 1.4%. RR, PFS, and OS for second-line S-1 were 17.2%, 2.5 Mo, and 7.8 Mo, respectively. PFS for Gem was not prognostic of PFS for S-1 (2.5 Mo both in pts with PFS >6Mo and in pts with PFS <6Mo for Gem). RS after PD for Gem was prolonged from 3.1 Mo in PreS-1 Group to 6.5 Mo in PostS-1 Group (p<0.001). The Cox hazard model revealed PreS-1 Group (HR2.42, p=0.001) in addition to male gender (HR1.83, p=0.019), poor PS (HR3.52, p<0.001), liver metastasis (HR2.36, p=0.037), elevated LDH (per 100U/L increase) (HR 1.30, p=0.046), elevated CRP (HR 1.14, p=0.023) at PD for Gem as poor prognostic factors of RS for Gem-refractory PaC. Conclusions: Introduction of S-1 might lead to improvement of prognosis in patients with Gem-refractory PaC. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document